Fig. 3: PSMD1 and PSMD3 are upregulated during CML disease progression.

RNA-seq data demonstrated increased PSMD1 (A) and PSMD3 (B) mRNA levels in mononuclear cells from BP-CML (n = 10) compared to CP-CML (n = 13) and AP-CML (n = 8) patients demonstrating BCR-ABL1-independent TKI resistance. C Immunoblot shows PSMD1 and PSMD3 protein levels in CD34+ cells from cord blood (lanes 1–2) versus a CP-CML patient (lane 3). β-actin was assessed as a loading control.